Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lypressin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A known ✓ | P37288 | 8/20 | 0.87 |
| ▸ | AVPR2 known ✓ | P30518 | 6/20 | 0.87 |
| ▸ | AVPR1B known ✓ | P47901 | 6/20 | 0.87 |
| ▸ | OXTR | P30559 | 10/20 | 0.87 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.82 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.82 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.82 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lypressin SCHEMBL33287 | 1.00 | OXTR (0.87) | OXTRAVPR1AAVPR2AVPR1BTBXA2R | |
| Lypressin SCHEMBL29471105 | 0.98 | OXTR (0.84) | OXTRAVPR1AAVPR2AVPR1BTBXA2R | |
| Ornipressin SCHEMBL1650220 | 0.98 | AVPR1A (0.88) | OXTRAVPR1AAVPR2AVPR1BTBXA2R | |
| Ornipressin SCHEMBL296322 | 0.98 | AVPR1A (0.88) | OXTRAVPR1AAVPR2AVPR1BTBXA2R | |
| SCHEMBL24239052 | 0.97 | OXTR (0.82) | OXTRAVPR1AAVPR2AVPR1BTBXA2R | |
| Felypressin SCHEMBL31138866 | 0.97 | AVPR1A (0.82) | OXTRAVPR1AAVPR2AVPR1BTBXA2R | |
| Felypressin SCHEMBL1650172 | 0.97 | AVPR1A (0.82) | OXTRAVPR1AAVPR2AVPR1BTBXA2R | |
| Felypressin SCHEMBL33291 | 0.97 | AVPR1A (0.82) | OXTRAVPR1AAVPR2AVPR1BTBXA2R | |
| Felypressin SCHEMBL361197 | 0.97 | AVPR1A (0.82) | OXTRAVPR1AAVPR2AVPR1BTBXA2R | |
| Ornipressin SCHEMBL4410141 | 0.97 | AVPR1A (0.85) | OXTRAVPR1AAVPR2AVPR1BTBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4577641-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEMOGENIC ENDOTHELIAL CELLS FROM PLURIPOTENT STEM CELLS | Trailhead Biosystems Inc. (US) | 2025-07-02 | — | — | EP | claimed |
| CN-119768510-A | Methods and compositions for producing hematopoietic endothelial cells from pluripotent stem cells | 特雷尔赫德生物系统股份有限公司 | 2025-04-04 | — | — | CN | claimed |
| WO-2024044347-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEMOGENIC ENDOTHELIAL CELLS FROM PLURIPOTENT STEM CELLS | TRAILHEAD BIOSYSTEMS INC. (US) | 2024-02-29 | — | — | WO | claimed |
| US-20240067932-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEMOGENIC ENDOTHELIAL CELLS FROM PLURIPOTENT STEM CELLS | TRAILHEAD BIOSYSTEMS INC. | 2024-02-29 | — | — | US | claimed |
| CN-115856149-B | Method for detecting impurities in terlipressin | 哈尔滨吉象隆生物技术有限公司 | 2023-12-05 | — | — | CN | claimed |
| US-20260000620-A1 | ORAL DOSAGE FORMS | AMRYT ENDO INC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4577641-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEMOGENIC ENDOTHELIAL CELLS FROM PLURIPOTENT STEM CELLS | Trailhead Biosystems Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| CN-119768510-A | Methods and compositions for producing hematopoietic endothelial cells from pluripotent stem cells | 特雷尔赫德生物系统股份有限公司 | 2025-04-04 | — | — | CN | disclosed |
| US-20240383944-A1 | SOLID PHASE PEPTIDE SYNTHESIS PROCESSES AND ASSOCIATED SYSTEMS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-11-21 | — | — | US | disclosed |
| EP-4463141-A1 | ORAL DOSAGE FORMS | Amryt Endo, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| US-11951149-B2 | Intranasal vasopressin treatment of social deficits in autism | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-04-09 | — | — | US | disclosed |
| US-20240067932-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEMOGENIC ENDOTHELIAL CELLS FROM PLURIPOTENT STEM CELLS | TRAILHEAD BIOSYSTEMS INC. | 2024-02-29 | — | — | US | disclosed |
| CN-115856149-A | Method for detecting impurities in terlipressin | 哈尔滨吉象隆生物技术有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-20220275021-A1 | SOLID PHASE PEPTIDE SYNTHESIS PROCESSES AND ASSOCIATED SYSTEMS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-09-01 | — | — | US | disclosed |
| CN-114126619-A | Compounds for the synthesis of peptidomimetics | 范因斯坦医学研究院 | 2022-03-01 | — | — | CN | disclosed |
| CN-113967248-A | Terlipressin acetate freeze-dried powder injection and preparation method thereof | 海南皇隆制药股份有限公司 | 2022-01-25 | — | — | CN | disclosed |
| CN-113318450-A | Task pushing method and device, storage medium and electronic equipment | 腾讯科技（深圳）有限公司 | 2021-08-31 | — | — | CN | disclosed |
| EP-3257863-A1 | FLOUROUS METABOLICALLY STABLE PEPTIDE ANALOGS | Université de Strasbourg (FR) | 2017-12-20 | — | — | EP | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000620-A1 | ORAL DOSAGE FORMS | PCTP, TAS2R13, MLEC | AVPR1A 666/4885AVPR2 1313/4885AVPR1B 974/4885 |
| US-11951149-B2 | Intranasal vasopressin treatment of social deficits in autism | AVPR1A, AVPR1B, AVPR2 | AVPR1A 1/4885AVPR2 3/4885AVPR1B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.